OrbiMed
Healthcare funds: Repeat prescription
An assortment of healthcare-focused GPs – most of them in China – have emerged to leverage rising domestic consumption and nascent medical innovation. Does domain expertise mean better deal access?
OrbiMed invests $42.5m in India's Vivimed Labs
Healthcare specialist investor OrbiMed has committed $42.5 million in Uquifa, the active pharmaceutical ingredient (API) unit of India-listed pharmaceuticals business Vivimed Labs.
Fund focus: OrbiMed scales up for Fund III
US-based healthcare specialist investor OrbiMed once again raises the bar with the closing of its oversubscribed third Asia fund
ADB re-ups in OrbiMed's Asia healthcare fund
The Asian Development Bank (ADB) has invested $60 million in OrbiMed Asia Partners III, the third Asian private equity fund of healthcare-focused GP OrbiMed.
OrbiMed closes third Asia healthcare fund at $551m
Healthcare-focused investment firm OrbiMed has closed its third Asian private equity fund with $551 million in commitments.
OrbiMed leads $30m round for China's Zai Lab
Zai Lab, a pharmaceutical company that licenses pre-clinical findings in the West for development into drugs in China, has received $30 million in Series C funding led by existing investor OrbiMed.
OrbiMed leads $19m round for Sino-US drug developer
OrbiMed Asia Partners has led a $19 million Series B round of funding for InventisBio, a pharmaceutical developer based in Shanghai with operations in China and the US.
True North invests $200m in India hospital chain
Indian private equity firm True North - formerly known as India Value Fund Advisors (IVFA) - has invested $200 million in domestic hospital chain Kerala Institute of Medical Sciences (KIMS).
AVCJ Awards 2016: Deal of the Year - Early Stage Tech: Zai Lab
Zai Lab has carved a niche licensing pre-clinical findings from the West for development into drugs in China, but its ambitions are global. Several VCs have faith in the project
PE-backed Claris exits division to US strategic
Claris Lifesciences, an Indian drug maker with several PE backers, has agreed to exit its injectables division to US-based generic pharmaceutical developer Baxter International.
OrbiMed, Chinese strategic to buy Canadian healthcare player
OrbiMed will consolidate its control of Canada-listed clinical equipment producer Response Biomedical in an C$11.1 million ($8.6 million) take-private deal including participation by Shanghai Runda Medical Technology.
Ex-New Horizon investors lead $100m round for Zai Lab
Advantech Capital, one of two new funds launched by executives from Chinese GP New Horizon Capital, has led a $100 million Series B round of funding for biotech start-up Zai Lab.
OrbiMed exits India's Ecron Acunova for $17.4m
Indian life-science technology company Take Solutions has agreed to pay INR1.15 billion ($17.4 million) for Ecron Acunova (EA), providing an exit for healthcare-focused private equity firm OrbiMed Advisors.
OrbiMed leads $50m round for India's Netmeds
Healthcare focused investment firm OrbiMed has led a $50 million round of funding for Indian online drug marketplace Netmeds.
China healthcare: Technology transfer
Healthcare-focused private equity firms want to take technologies from developed markets into China, leveraging rising domestic demand. It is a lucrative strategy, but not necessarily a straightforward one
US medical device maker gets $51m for China expansion
MID Labs, a US-based medical devices manufacturer that focuses on eye surgery, has received $51 million in funding from a group of investors to support its expansion into China.
OrbiMed commits $15m to China's GC-Rise Pharma
OrbiMed has committed $15 million in Series B funding to GC-Rise Pharmaceutical, a Chinese healthcare services provider.
ADB commits $60m to OrbiMed's second Asia fund
The Asian Development Bank (ADB) is to commit up to $60 million to Orbimed Advisors' second Asian healthcare fund - OrbiMed Asia Partners II.
OrbiMed targets $300m for second Asia healthcare fund
Healthcare-focused private equity firm OrbiMed Advisors is targeting $300 million for its second Asia fund. The PE firm raised $188 million for its debut regional vehicle in 2008.
OrbiMed launches Asia healthcare fund
Healthcare-focused PE firm OrbiMed Advisors will launch its second Asian healthcare fund towards the end of 2013, with a target of $500 million.